IGM Biosciences amasses $102 mln Series C
Mountain View, California-based IGM Biosciences Inc, a biotech firm focused on developing engineered IgM antibodies for therapeutic use, has raised $102 million in Series C financing. The investors included Redmile Group, Janus Henderson Investors and Vivo Capital.
9 July 2019•1 min read
